Huayi Pharmaceuticals (Anhui) Co., Ltd. is the first pharmaceutical company passing European certification in Anhui and dedicated to providing CDMO services for oral preparations. The company focuses on manufacturing and R&D and expand services into areas such as API development and clinical services etc. Moreover, Huayi actively innovate its service model to provide services such as Joint venture cooperation, MA application in both China and Europe etc. to assist customers to secure a competitive edge in the pharmaceutical markets.
Since its establishment, Huayi has been committed to providing comprehensive, high-quality CDMO services for oral preparations to pharmaceutical companies worldwide and has successfully passed 5 EU certifications and over 40 domestic and international official inspections. With its quality advantages and standardized operations under system with dual certification in China & Europe, Huayi has earned wide recognition and acclaim within the industry. Through years of dedication, Huayi has gradually built an open CDMO platform for international markets with oral preparation manufacturing at its core, contributing significantly to the development of the global pharmaceutical industry.
Adhering to the corporate value of “For a better world”, Huayi consistently prioritizes social benefits and is committed to improving public health. Upholding the corporate spirit of “For people’s health”, Huayi provides customers with services of high efficient, high quality and controllable cost through pragmatic execution, evidence-based approaches, and bold innovation and remain steadfast in our mission to make high quality drugs at affordable cost. Looking ahead, Huayi sincerely looks forward to cooperating with our customers to expand both domestic and international pharmaceutical markets and to contribute to a healthier future for humanity.
tablets/capsules manufactured per year on a contract basis
products successfully developed and commercialized
? Passed the fifth EU inspection in November 2024
? Synthesis laboratory constructed
? Phase I Preparation Building in the New Site
(Shenyang Road Site) Put Into Use
? High potent solid preparation workshop under
construction
? The Fourth Council Member Unit of the All-China
Federation of Industry and Commerce Association
of Pharmaceutical Commerce
? Top 20 Chinese Pharmaceutical CDMO Enterprises
in 2023
? Main Structure Construction for Phase I Preparation
Building in the New Site (Shenyang Road Site)
completed
? Construction of synthesis laboratory started
? Construction of highly potent solid preparation
workshop started
? Exports to EU reached 2.5 billion tablets
? First domestic product commercialized
? On September 13, 2022, the company was elected
as the Chairman Unit of Anhui Preparation CDMO
Industry Alliance
? Top 20 Chinese Pharmaceutical CDMO Enterprises
in 2022
? 2022 (Industry) Leading Enterprise
? On October 8, 2021, Huayi’s Technical Center was
established.
? In June 2021, the company passed the remote
re-inspection by MHRA.
? On July 14, 2020, Huayi produced the first bottle of
oral liquids preparation with the Oral Liquid
Preparation Workshop put into operation.
? In 2019, we were named as one of the Top 50 Growing
Enterprise of the Chinese Pharmaceutical Industry.
? In 2018, contract manufacturing output reached
1.6 billion units and we began construction of our
oral liquid preparation workshop and high-potency
workshop.
? In 2016, the company passed re-inspection by MHRA
without any major deficiencies. The workshop
extension passed MHRA certification and the
company’s annual capacity was increased to 3 billion
units.
? In 2012, the company passed re-inspection by MHRA.
? In 2010, we passed the on-site inspection by MHRA and
received EU GMP certification. We became the 12th
solid dose pharmaceutical plant to pass EU GMP
accreditation in China. We started manufacture for the
EU market.
? In 2006, Huayi Pharmaceutical (Anhui) Co., Ltd., a
Sino-British joint venture, was established. Land
was purchased and the factory designed.
